Individual prognosis in patients who are HIV-infected but still asymptomatic or in clinical stages
Abbreviations: AIDS = Acquired immunodeficiency syndrome; ARC = AIDS-related complex; CD = Clusters of leukocyte differentiation; CDC = Centers of Disease Control; CMV = Cytomegalovirus infection; ELISA=Enzyme-linked immunosorbent assay; GTP = Guanosine triphosphate; HIV = Human immunodeficiency syndrome (= HIV-I in this paper); IVD = Intravenous drug abuser; KS = Kaposi's sarcoma; PGL = Persistent generalized lymphadenopathy; PcP=Pneumocystis carinii pneumonia; SD = Standard deviation such as persistent generalized lymphadenopathy (PGL) or AIDS-related complex (ARC) is needed both for the information of the infected subject as well as for therapeutic decisions.
It has been shown that clinical symptoms (oral candidiasis, hairy leukoplakia), immunological parameters (changes of helper lymphcytes (CD4), immunoglobulins), and hematological parameters (changes in hemoglobin, white-cell counts, platelets) are associated with the later development of AIDS in HIV-infected patients [1, 6] .
The objective of our study was to compare the prognostic relevance of laboratory parameters (neopterin, CD4 cells, CD8 cells, lymphocytes, platelets, hemoglobin, gammagtobulins, erythrocyte sedimentation rate) in HIV-infected patients.
Methods
Fifty-six HIV-infected patients (HIV seropositive in ELISA and Western blot) were studied over a mean observation period of 12 months (range, 5 to 33 months). All patients were seen in intervals of at least 6 months in our outpatient clinic and evaluated on the ward if opportunistic infections required hospitalization. Retrospectively the patients were subdivided in two groups: patients in group 1 developed AIDS within the observation period, whereas patients in group 2 did not develop AIDS according to the CDC criteria. The clinical diagnoses are given in Table 1 .
The mean age was 33.8 years, 49 patients were homo-or bisexual men, 9 patients were intravenous drug abusers (IVD), 4 of the 56 patients were women ( Table 2) .
The complete patient examination included: medical history, physical examination, immunological parameters, and neopterin (Radioimmunoassay manufactured by Henning, West Berlin) [8] . Eight potential predictor variables measured on each patient at the beginning of the observation In a linear discriminant analysis, a stepwise entry of these variables into the discriminant function was effected according to which variable added most to the separation into groups 1 and 2. Sensitivity was defined as the proportion of patients with neopterin levels of 22 nmol/1 and above among patients in group 1. Specificity was defined as the proportion of patients with neopterin levels below 22 nmol/1 in group 2. 
Results
Neopterin proved to be most discriminating with no improvement of separation when adding further variables. Mean neopterin levels in group 2 were 14.4 (_+4.6) nmol/1 vs 29.7 (_+11.7) nmol/1 in group 1. Mean values of the other parameters are given in Table 3 .
A final allocation rule was computed using neopterin alone. This rule assigns neopterin levels of 22 nmol/1 and over to group 1 and levels below to group 2. Nine group 1 patients and 41 group 2 patients were correctly classified by the allocation rule when applied to the same sample. These numbers translate to a sensitivity of 9/11 (82%) and a specificity of 41/45 (89%) ( Table 4) .
Discussion
Neopterin is a metabolite in the biosynthesis of tetrahydrobiopterin, which is known to be a cofactor for the hydroxylases needed for the biosynthesis of catecholamines and serotonin. Elevated serum and urinary neopterin levels are related to activity in cell-mediated immune response [5] . Neopterin is synthesized mainly in macrophages and neuroendocrinologic tissues.
Guanosine-triphosphate (GTP) is metabolized into dihydro-neopterin-triphosphate by GTP-cyclohydroxylase. The enzyme dihydrobiopterin synthetase catalyzes the synthesis of tetrahydrobiopterin from dihydrobiopterin-triphosphate (speedlimiting step). Surplus dihydrobiopterin-triphosphate is excreted eventually as dihydroneopterin and neopterin [3] . The biological function of these metabolic products is not known.
Increased neopterin levels are assumed to reflect an increase in the GTP pool and GTP-cyclohydroxylase activity as observed in stimulated monocytes [3] .
In our study 9/11 patients with neopterin serum levels of 22 and over were correctly allocated to group I -those patients who developed AIDS within the mean observation period of 12 months (sensitivity 9/11; 82%). Neopterin was found to be most discriminating between groups 1 and 2 when compared with CD4, CD8, hemoglobin, platelets, gammaglobulins, and ESR. An allocation rule based on neopterin alone yielded a highly satisfactory sensitivity and specificity in the range of 80%-90%.
Nevertheless, some comment on patients misallocated may be in order (Table 5) . One of these patients was an intravenous drug abuser who suffered from arthralgias and myalgias at the time of the first neopterin elevation (23.5 nmol/1) which might reflect a viral infection. Common viral infections are known to cause a transient neopterin rise [7] . His neopterin level 1.5 years later had decreased to 16.8 nmol/1 and he remained free of AIDS for another year after the 16.8 value. This suggests that the specificity of allocation could be improved when elevated neopterin levels are confirmed by a second value.
Another patient who was allocated as "falsely positive" (neopterin 22.0 and 22.4 nmol/1 1.5 years later) showed a persistent rise of liver transaminases and was positive for hepatitis-B surface antigen. Hepatitis B and cytomegalovirus-infection (CMV) are known to result in a neopterin rise [2] .
The third "falsely positive" patient (neopterin 30.0 nmol/1) showed a subclinical seroconversion for CMV. He remained free of AIDS in the following year and his neopterin fell to 26.0 nmol/1.
The fourth such patient suffered from chronic diarrhea. Half a year prior to our evaluation Entamoeba histolytica had been diagnosed. Infection with intracellular parasites and all other microor-ganisms that are eliminated by cetlular immune defence (including mycobacteria) are known to cause a neopterin rise [4] . This patient could be treated successfully, neoptefin was 11.4 nmol/1 14 months later.
Of 11 patients two were allocated "falsely negative" by our allocation rule. One had a mild episode of Pneumocystis carinii pneumonia (PcP; neopterin 1 year prior to PcP was elevated to 19.8 nmol/1 and was 31.0 nmol/l at diagnosis of PcP). The other patient in this category developed Kaposi's sarcoma (KS) without opportunistic infection (neopterin 10.5 nmol/1 1 year before and 13.6 nmol/1 at time of AIDS diagnosis due to KS).
Neopterin rise reflects a stimulation of cellular defence mechanisms [3, 4] . Chronic and subclinical or latent infections with CMV, PcP, mycobacteria or other frequent opportunistic infectious agents in AIDS probably result in a stimulation of macrophages which leads to a rise in neopterin levels. Elevations of neopterin levels in HIV-positive subjects may therefore be seen as an important indication of subclinical infection with a propensity toward progression to AIDS.
